Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.69 and traded as high as $0.83. Brainstorm Cell Therapeutics shares last traded at $0.8295, with a volume of 32,971 shares traded.
Brainstorm Cell Therapeutics Price Performance
The company has a market capitalization of $8.28 million, a price-to-earnings ratio of -0.22 and a beta of 0.30. The business has a fifty day moving average price of $0.77 and a 200 day moving average price of $0.69.
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical?stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Recommended Stories
- Five stocks we like better than Brainstorm Cell Therapeutics
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
